| Nome |
# |
|
Mepolizumab in severe asthma: evidence in real-life, file e268c4cc-94ad-a6b7-e053-3a05fe0adea1
|
347
|
|
The safety of monoclonal antibodies in asthma, file e268c4cb-4c52-a6b7-e053-3a05fe0adea1
|
214
|
|
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment, file e268c4cb-bac1-a6b7-e053-3a05fe0adea1
|
206
|
|
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma?, file e268c4ca-aac0-a6b7-e053-3a05fe0adea1
|
179
|
|
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma, file e268c4ca-b837-a6b7-e053-3a05fe0adea1
|
124
|
|
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials, file e268c4ca-d88d-a6b7-e053-3a05fe0adea1
|
111
|
|
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma, file e268c4ca-8bbd-a6b7-e053-3a05fe0adea1
|
95
|
|
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience, file e268c4ca-a76b-a6b7-e053-3a05fe0adea1
|
58
|
|
Personalized medicine in allergy, file e268c4ca-b41a-a6b7-e053-3a05fe0adea1
|
56
|
|
Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy, file e268c4cb-8cca-a6b7-e053-3a05fe0adea1
|
56
|
|
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations, file e268c4cb-bac0-a6b7-e053-3a05fe0adea1
|
43
|
|
Evolving phenotypes to endotypes: is precision medicine achievable in asthma?, file e268c4cb-d437-a6b7-e053-3a05fe0adea1
|
23
|
|
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy, file e268c4cc-c929-a6b7-e053-3a05fe0adea1
|
21
|
|
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19, file d85263f2-9548-4fd3-882d-90fbcf198e12
|
18
|
|
30 Years Of Sublingual Immunotherapy, file e268c4cb-a6aa-a6b7-e053-3a05fe0adea1
|
11
|
|
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19, file e268c4cc-cdbb-a6b7-e053-3a05fe0adea1
|
10
|
|
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation, file e268c4ca-b7be-a6b7-e053-3a05fe0adea1
|
9
|
|
Biological agents for severe asthma: the evolution of the at-home self-injection approach., file e268c4cd-09dd-a6b7-e053-3a05fe0adea1
|
9
|
|
null, file e268c4cd-7625-a6b7-e053-3a05fe0adea1
|
9
|
|
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life, file e268c4cd-448a-a6b7-e053-3a05fe0adea1
|
8
|
|
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments, file b32882f5-b11f-4739-891f-22dc8680c057
|
7
|
|
Severe asthma, biologicals, and auto-injection: Yes, no, may be!, file e268c4ca-cf3e-a6b7-e053-3a05fe0adea1
|
6
|
|
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy, file f2e2c9fe-0015-4107-81ef-fb915010dffd
|
6
|
|
The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with Mepolizumab in real life, file e268c4cb-992a-a6b7-e053-3a05fe0adea1
|
5
|
|
One year of mepolizumab. Efficacy and safety in real-life in Italy, file e268c4ca-dcb6-a6b7-e053-3a05fe0adea1
|
4
|
|
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19, file e268c4cf-0177-a6b7-e053-3a05fe0adea1
|
4
|
|
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies, file e268c4c8-85e3-a6b7-e053-3a05fe0adea1
|
3
|
|
Umeclidinium for the treatment of uncontrolled asthma, file e268c4ca-be5b-a6b7-e053-3a05fe0adea1
|
3
|
|
Biosimilars in allergic diseases, file e268c4ca-f702-a6b7-e053-3a05fe0adea1
|
3
|
|
Impact of tDCS on persistent COVID-19 olfactory dysfunction: a double-blind sham-controlled study, file e268c4cf-0b0c-a6b7-e053-3a05fe0adea1
|
3
|
|
Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies, file 5863516d-ea73-4e4b-a554-9c9ddd692662
|
2
|
|
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis, file e268c4ca-a909-a6b7-e053-3a05fe0adea1
|
2
|
|
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases, file e268c4ca-bc18-a6b7-e053-3a05fe0adea1
|
2
|
|
Update on immunotherapy for the treatment of asthma, file e268c4ca-d119-a6b7-e053-3a05fe0adea1
|
2
|
|
Biologicals for severe asthma: what we can learn from real-life experiences?, file e268c4cd-0167-a6b7-e053-3a05fe0adea1
|
2
|
|
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?, file e268c4cd-20f5-a6b7-e053-3a05fe0adea1
|
2
|
|
Severe asthma: One disease and multiple definitions, file e268c4ce-1b89-a6b7-e053-3a05fe0adea1
|
2
|
|
Quick Olfactory Sniffin’ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients, file 12acfdd0-2da7-4c27-aa9c-cdb49471d6f7
|
1
|
|
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps, file 273d79ee-7979-45d3-b592-ebf394755e15
|
1
|
|
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life, file e268c4ca-9a50-a6b7-e053-3a05fe0adea1
|
1
|
|
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma, file e268c4ca-a767-a6b7-e053-3a05fe0adea1
|
1
|
|
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation, file e268c4ca-da59-a6b7-e053-3a05fe0adea1
|
1
|
|
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma, file e268c4ca-e008-a6b7-e053-3a05fe0adea1
|
1
|
|
Current insights in allergen immunotherapy, file e268c4cb-240b-a6b7-e053-3a05fe0adea1
|
1
|
|
The path to personalized medicine in asthma, file e268c4cb-fa23-a6b7-e053-3a05fe0adea1
|
1
|
|
Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study, file e268c4cc-1f6c-a6b7-e053-3a05fe0adea1
|
1
|
|
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity, file e268c4cd-c3e1-a6b7-e053-3a05fe0adea1
|
1
|
| Totale |
1.675 |